Call Us : +603-9010-3058
Email Us : This email address is being protected from spambots. You need JavaScript enabled to view it.

You are here: Home Publications, News & Events News & Events

Sunday17 February 2019

Bernama : Penawar Kanser Tahap Lewat


KUALA LUMPUR, 24 Okt (Bernama) -- Terdapat harapan baru untuk pesakit kanser di Malaysia.

Sebuah vaksin yang terkenal bagi meraw at kanser tahap lew at -- hampir semua jenis kanser kecuali leukemia -- kini diperolehi di negara ini.

Vaksin Human Initiated Therapeutic Vaccine (HITV), yang hanya didapati di Jepun sebelum ini, mampu memusnahkan sarang sel mikroskop dan kecil, sekali gus mencegah sebarang serangan kanser berulang.

Vaksin tersebut ditemui pada 2005 oleh pakar perubatan dan penyelidik Jepun, Dr Kenichiro Hasumi dan HITV merupakan imunoterapi yang menghasilkan sel aktif pesakit sendiri bagi metastatik atau pesakit tahap lewat kanser.

Read more ...

Astro Awani : interviews Dr. Hasumi

HITV is part of an international collaboration in the FDA clinical trial of HITV therapy in late stage cancer patients led by the University of Maryland, USA ( Project Name: "Autologous Dendritic Cells Derived From Peripheral Blood Mononuclear Cells Cultured with Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-4 ( CellGenix ); Administered Intratumoral" ).

The Human Initiated Therapeutic Vaccine, which was developed by Dr Kenichiro Hasumi, is an autologous (patient derived) active cell based immunotherapy for patients who are suffering from late stage or metastatic cancer. Dr Hasumi is the founder of Hasumi International Research Foundation ( www.hasumi-foundation.org )

Dr Hasumi's protocol has been found to be highly effective when used in combination with radiotherapy, and is a source of hope for cancer patients who already have metastases ( i.e the cancer has spread to other parts of the body ).


HITV Lab is involved in cell-based biotechnology medical applications with special focus on Dendritic Cell-Based Immunotherapy for cancer. HITV Lab is committed to support an international collaboration in the FDA clinical trial of HITV Therapy in late-stage cancer patients led by the University of Maryland, USA.

FacebookTwitterGoogle Bookmarks